Clinical Cancer Research · 2007 · 346 citations · 30 references
Life SciencesImmunologyOncologyCellular ImmunologyImmunotherapyNeuroimmunologyCancer ImmunotherapyCell-mediated ImmunityCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsRegulatory T CellsT Cell BiologyCd4 Positive T Cell ResponsesCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesCtla-4 InhibitionCtla-4-mediated RegulationCytotoxic T-lymphocyte-associated Protein 4 InhibitorsExperimental Autoimmune EncephalomyelitisRegulatory T Cell Defects
PURPOSE: Patients with malignant glioma suffer global compromise of their cellular immunity, characterized by dramatic reductions in CD4(+) T cell numbers and function. We have previously shown that increased regulatory T cell (T(reg)) fractions in these patients explain T-cell functional deficits. Our murine glioma model recapitulates these findings. Here, we investigate the effects of systemic CTLA-4 blockade in this model. EXPERIMENTAL DESIGN: A monoclonal antibody (9H10) to CTLA-4 was employed against well-established glioma. Survival and risks for experimental allergic encephalomyelitis were assessed, as were CD4(+) T cell numbers and function in the peripheral blood, spleen, and cervical lymph nodes. The specific capacities for anti-CTLA-4 to modify the functions of regulatory versus CD4(+)CD25(-) responder T cells were evaluated. RESULTS: CTLA-4 blockade confers long-term survival in 80% of treated mice, without eliciting experimental allergic encephalomyelitis. Changes to the CD4 compartment were reversed, as anti-CTLA-4 reestablishes normal CD4 counts and abrogates increases in CD4(+)CD25(+)Foxp3(+)GITR(+) regulatory T cell fraction observed in tumor-bearing mice. CD4(+) T-cell proliferative capacity is restored and the cervical lymph node antitumor response is enhanced. Treatment benefits are bestowed exclusively on the CD4(+)CD25(-) T cell population and not T(regs), as CD4(+)CD25(-) T cells from treated mice show improved proliferative responses and resistance to T(reg)-mediated suppression, whereas T(regs) from the same mice remain anergic and exhibit no restriction of their suppressive capacity. CONCLUSIONS: CTLA-4 blockade is a rational means of reversing glioma-induced changes to the CD4 compartment and enhancing antitumor immunity. These benefits were attained through the conferment of resistance to T(reg)-mediated suppression, and not through direct effects on T(regs).
30
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison · Science · 1996 · 3.9K citations
Life Sciences, Immunology, Oncology +17
Takeshi Takahashi, Tomoyuki Tagami, Sayuri Yamazaki et al. · The Journal of Experimental Medicine · 2000 · 2.2K citations · Full text
Life Sciences, Immunology, Pathology +17
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al. · Immunity · 1994 · 2.2K citations
Simon Read, Vivianne Malmström, Fiona Powrie · The Journal of Experimental Medicine · 2000 · 2.2K citations
Giao Q. Phan, James Chih‐Hsin Yang, Richard M. Sherry et al. · Proceedings of the National Academy of Sciences · 2003 · 1.6K citations · Full text
Life Sciences, Immunology, Oncology +17